RESUMO
Introduction: Mutation of the P53 gene is thought to stimulate cell growth and to be involved in the development and progression of tumors
Objective: The aim of this study was to survey the relationship of P53 with other clinic pathological parameters such as size of tumor, grade of malignancy, lymph vascular attacks, and also its correlation with the condition of steroid receptors in breast cancer patients [BCP]
Materials and Methods: The study samples were chosen from 465 BCPs who had breast surgery or excistonal biopsy. Immunohistochemistery method was applied for the detection of estrogen and progesterone receptor and HER2 and P53. According to hormone receptor status, cases were either hormone receptor positive [ER+ or PR+] or hormone receptor negative [ER- and PR-]. We divided patients into two groups: low grade instead of grade1, and high grade instead of grade 2 and 3
Results: 29.7% of our 465 cases were P53 positive. The mean age of P53negative cases was significantly more than P53 positive ones. [49.2 y/o vs. 46.7 y/o] P53 protein Expression correlated positively with HER2 protein expression. [P=0.000]. P53 negativity and hormone receptor positivity had a positive correlation with low-grade tumor [P=0.007]. There were no significant correlation between P53 and lymphovascular invasion and relapse and tumor size
Conclusion: Our results show that tumors of low malignant potential [grade1] have an immunophenotype of P53-, ER+, PR+, while high grade tumors [grade3] frequently express a P53+ and ER-, PR- phenotype. Negativity of P53 has a significant correlation with good prognostic factors like hormone receptor positive and low gradity, so evaluation of biologic marker of P53 is helpful to select the protocol of treatment in patients with equal stages